drugset
drugset / Trial / NCT04107740

C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration

NCT04107740 ↗

Phase 4 Completed 160 enrolled HLB Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to evaluate the efficacy and safety of C-Trelin OD Tablet 5mg(Taltirelin Hydrate) in Multicenter, randomized, double-blind, placebo-controlled clinical trial in patients with ataxia induced by spinocerebellar degeneration.

Timeline

Start
2019-03-04
Primary completion
2021-02-08
Completion
2021-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Taltirelin Protein / enzyme biologic 5 mg —

Indications

cerebellar degeneration